Colonoscopy is increasingly the preferred method for colon cancer screening, 1 but its high cost in the United States has been scrutinized. 2 Unnecessary colonoscopies contribute to societal costs, 3 and the cost per procedure is high. For example, anesthesiologists or nurse anesthetists often administer sedation for endoscopies in low-risk patients, adding more than $1 billion of potentially unnecessary costs annually. 4 The cost of gastroenterology office visits before colonoscopy has received less attention. Widely accepted guidelines for colon cancer screening and polyp surveillance and the generally low risk of colonoscopy may obviate the need for many of these visits. Open-access endoscopy, which allows patients to be referred for endoscopies without a prior gastroenterology office visit, began in the United States in the 1990s, 5 though recent estimates of the
prevalence of the practice are lacking. We analyzed billing data to determine the proportion of colonoscopies for colon cancer screening and polyp surveillance that were preceded by office visits and the associated payments for those visits.
Methods | We used MarketScan Commercial Claims and Encounters (Truven Health Analytics) from 2010 through 2013. The database contains use and expenditure data for individuals with employer-sponsored private health insurance from several hundred US employers and health plans and includes approximately 43 to 55 million beneficiaries each year from all 50 states. We included patients aged 50 to 64 years with continuous insurance coverage for 12 months prior to an outpatient colonoscopy performed in the gastroenterology setting that included a diagnosis for screening or polyp surveillance. This study was deemed exempt by the Johns Hopkins University institutional review board.
We excluded patients with diagnosis codes for colon cancer or inflammatory bowel disease in the preceding 12 months and patients who underwent esophagogastroduodenoscopy on the same day as colonoscopy. Gastroenterology office visits were identified by outpatient evaluation and management codes (new patient, established patient, or consultation) in the 6 weeks prior to colonoscopy. To increase the likelihood that office visits were related to colonoscopy, we excluded patients with gastroenterology office visits between 6 weeks and 1 year prior to colonoscopy. Total payments included those made by insurance plans and patients for those office visits.
Results | Of 842 849 patients who underwent colonoscopy, 247 542 (29.4%; 95% CI, 29.3%-29.5%) had a precolonoscopy office visit ( Table 1) . Patients with office visits had a higher Charlson Comorbidity Index (CCI) and were more likely to reside in the South. Of patients with office visits, 66.4% had a CCI of 0. Of the office visits, 77.4% were associated with a diagnosis of either screening or preoperative evaluation ( Table 2) . Mean payment for office visits was $123.83. Distributed across all patients, precolonoscopy office visits added a mean of $36.37 per colonoscopy.
Discussion | Even though open-access colonoscopy has been available in the United States for more than 20 years, we found that approximately 30% of colonoscopies for colon cancer screening and polyp surveillance were preceded by a gastroenterology office visit. The primary limitation of this study is that we were unable to determine the exact circumstances of office visits. Patients or referring clinicians may have requested office visits prior to the procedure, and we did not determine whether individual office visits were necessary or appropriate. The higher CCI among patients with office visits indicates some selection of patients at higher risk of adverse events for office visits, suggesting that our estimate is likely the upper limit of office visits that could be averted through increased direct access.
We were unable to determine whether office visits prevented any unnecessary colonoscopies or improved the safety or clinical value of the colonoscopy. Our population included only younger individuals (<65 years) with private insurance, so our findings may not be generalizable to other populations.
Although the precolonoscopy office visits added a modest $36 per colonoscopy in this population, there are an estimated 7 million screening colonoscopies performed in the United States annually, 6 so the cumulative costs are significant. Identifying which patients benefit from a precolonoscopy office visit and targeting those patients could increase the value of colon cancer screening. 
COMMENT & RESPONSE

Oral Nutrient Supplementation and Cognitive Function
To the Editor The study by Dr Chew and colleagues 1 found that oral supplementation with omega-3 long-chain polyunsaturated fatty acids (LCPUFAs) or lutein/zeaxanthin had no effect on cognitive function in older persons with age-related macular degeneration. We are concerned about a number of conceptual and methodological issues. First, the authors described this ancillary study as a randomized, double-masked, placebo-controlled, 2 × 2 factorial trial. They also stated "All participants were also given varying combinations of vitamins C, E, beta carotene, and zinc." Therefore, LCPUFAs and lutein/zeaxanthin were not compared with a placebo. Rather, they were added to other nutrients already shown to be effective at reducing risk for central neurodegenerative disease.
2-4 A more appropriate conclusion would be that additive nutrition, in a population described as well-nourished, was not more effective than the original formulation at influencing cognitive function in older persons experiencing visual impairment. Second, the authors stated that the study "was powered to evaluate only the main effects of omega-3 LCPUFAs." If the study has insufficient power to detect other differences, it cannot, by definition, state that no other differences, particularly for lutein and zeaxanthin, exist.
Third, when individual, domain-specific functional tests are combined into a composite, as they were in this study, domain specificity is lost. This is important given that cognition does not tend to decline across all domains at the same rate, and this sample was likely at risk for cognitive decline. 3, 4 
